EMA consults on trial database transparency challenge
This article was originally published in Scrip
In the latest stage in the EU's efforts to widen the publication of clinical trial data, the European Medicines Agency has opened a public consultation on how to decide exactly what information should be available in the future clinical trials database, which will be accessible to the general public.
You may also be interested in...
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.
Coronavirus Notebook: New Therapeutic Approaches, Fair Access To Dexamethasone, & Patent Help From The EPO
With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.